Celcius Launches Rs 500 Million Pharma Logistics Arm
WAREHOUSING & LOGISTICS

Celcius Launches Rs 500 Million Pharma Logistics Arm

Celcius Logistics, India’s leading tech-driven 3PL and cold supply chain provider, has launched Celcius+, a dedicated vertical for the seamless management of the pharmaceutical supply chain. The new arm is designed to meet the sector’s stringent demands for temperature control, compliance, and real-time visibility, ensuring safe and efficient transport of medicines, vaccines, and other sensitive products.
In its first phase, the company will invest Rs 500 million to build a dedicated pharma fleet and supporting infrastructure, aiming to generate Rs 1 billion in annual recurring revenue (ARR) from this vertical within 18 months. Of this, Rs 350 million will be used to deploy 100 new reefer vehicles along key pharmaceutical corridors across India, while Rs 100–150 million is earmarked for developing a robust pharma courier system for high-demand urban and semi-urban markets.
To drive this expansion, Celcius will hire 30–40 specialists in pharma logistics, operations, and compliance. Leveraging its advanced tech platform, Celcius+ will provide real-time tracking, continuous temperature monitoring, and AI-enabled route optimisation, ensuring shipments comply with the highest quality standards.
Founder and CEO Swarup Bose said: “With Celcius+, we are expanding capacity while setting new benchmarks for safety, transparency, and operational excellence in pharma logistics. Our investment marks the start of a focused journey to reduce wastage, ensure compliance, and bridge gaps in pharma distribution with technology-driven solutions.”
Celcius+ plans to partner with leading pharmaceutical companies and extend its reach to over 100 cities by the end of 2025. Its services will cover primary and secondary distribution, as well as last-mile pharma courier delivery for high-value products including vaccines, biologics, insulin, and specialty medicines.
The 24-ft reefer fleet will be equipped with advanced telematics, digital lock systems, CCTV surveillance, and 24/7 tracking via a central control tower. This infrastructure is designed to guarantee product integrity and fast response to any disruptions.
Earlier this year, Celcius Logistics raised Rs 2.5 billion in an oversubscribed Series B round to accelerate technology upgrades and network expansion. Currently operating across 600 cities, the company aims to scale to more than 1,000 cities in the coming years, with Celcius+ strengthening its presence in pharmaceutical logistics.

Celcius Logistics, India’s leading tech-driven 3PL and cold supply chain provider, has launched Celcius+, a dedicated vertical for the seamless management of the pharmaceutical supply chain. The new arm is designed to meet the sector’s stringent demands for temperature control, compliance, and real-time visibility, ensuring safe and efficient transport of medicines, vaccines, and other sensitive products.In its first phase, the company will invest Rs 500 million to build a dedicated pharma fleet and supporting infrastructure, aiming to generate Rs 1 billion in annual recurring revenue (ARR) from this vertical within 18 months. Of this, Rs 350 million will be used to deploy 100 new reefer vehicles along key pharmaceutical corridors across India, while Rs 100–150 million is earmarked for developing a robust pharma courier system for high-demand urban and semi-urban markets.To drive this expansion, Celcius will hire 30–40 specialists in pharma logistics, operations, and compliance. Leveraging its advanced tech platform, Celcius+ will provide real-time tracking, continuous temperature monitoring, and AI-enabled route optimisation, ensuring shipments comply with the highest quality standards.Founder and CEO Swarup Bose said: “With Celcius+, we are expanding capacity while setting new benchmarks for safety, transparency, and operational excellence in pharma logistics. Our investment marks the start of a focused journey to reduce wastage, ensure compliance, and bridge gaps in pharma distribution with technology-driven solutions.”Celcius+ plans to partner with leading pharmaceutical companies and extend its reach to over 100 cities by the end of 2025. Its services will cover primary and secondary distribution, as well as last-mile pharma courier delivery for high-value products including vaccines, biologics, insulin, and specialty medicines.The 24-ft reefer fleet will be equipped with advanced telematics, digital lock systems, CCTV surveillance, and 24/7 tracking via a central control tower. This infrastructure is designed to guarantee product integrity and fast response to any disruptions.Earlier this year, Celcius Logistics raised Rs 2.5 billion in an oversubscribed Series B round to accelerate technology upgrades and network expansion. Currently operating across 600 cities, the company aims to scale to more than 1,000 cities in the coming years, with Celcius+ strengthening its presence in pharmaceutical logistics.

Related Stories

Gold Stories

Next Story
Infrastructure Energy

Asian Energy Services Q1 FY27 PAT Rises 129 Per Cent

Asian Energy Services Limited reported a 129 per cent year-on-year rise in net profit to Rs 128 million for Q1 FY27, compared with the corresponding quarter last year.Revenue increased 135 per cent year-on-year to Rs 2.71 billion, supported by continued momentum across its services business, disciplined execution and contributions from domestic and international operations. EBITDA grew 81 per cent year-on-year during the quarter.As of June 30, 2026, the company’s standalone order book stood at Rs 17.54 billion, with around 60 per cent coming from oil and gas services and 40 per cent from min..

Next Story
Infrastructure Urban

BioBTX to Build First Commercial-Scale Circular Chemicals Plant

Dutch circular chemistry technology developer BioBTX is building what it says will be the world’s first commercial-scale plant to convert mixed plastic waste into high-quality aromatic chemicals using its proprietary Integrated Catalytic Cracking Process (ICCP) technology.The facility will be built at Chemical Park Delfzijl on the northern coast of the Netherlands and is expected to create 35 jobs. Covestro, which has been a shareholder and strategic partner of BioBTX since 2024, holds a mid-single-digit million-euro investment in the company.BioBTX’s ICCP technology uses catalytic pyrolys..

Next Story
Real Estate

Awfis Q1 FY27 PAT Jumps 140% as Revenue Rises 27%

Awfis Space Solutions reported a 140 per cent year-on-year rise in consolidated profit after tax (PAT) to Rs 240 million for Q1 FY27, compared with Rs 100 million in the corresponding quarter last year.Revenue from operations increased 27 per cent to Rs 4.25 billion from Rs 3.35 billion, while EBITDA rose 28 per cent to Rs 1.62 billion. EBITDA margin improved to 38.2 per cent from 37.8 per cent. Profit before tax increased 135 per cent to Rs 240 million.The company's co-working business recorded 27 per cent year-on-year growth, supported by demand from enterprises, Global Capability Centres (G..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement